Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript Summary
Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript Summary
The following is a summary of the Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript:
以下是Twist Bioscience公司(TWST)2024年第四季度业绩会文本摘要:
Financial Performance:
财务表现:
Twist Bioscience reported a record quarter with revenue reaching $84.7 million, marking a 27% year-over-year increase and 4% sequentially.
Annual revenue for fiscal year 2024 rose to $330 million, a 28% increase from the previous year.
Gross margin for Q4 was reported at 45.1%, surpassing guidance and showing significant improvement from the previous fiscal year's 36.6%.
Cash, cash equivalents, and short-term investments ended at $276.4 million as of September 30, 2024.
Twist Bioscience报告称,营业收入达到8470万美元,创下历史新高,同比增长27%,环比增长4%。
2024财年的年度营业收入达到33000万美元,比上一年增长28%。
第四季度毛利率报告为45.1%,超过预期,较上一财年36.6%有显著改善。
截至2024年9月30日,现金、现金等价物和短期投资总额为27640万美元。
Business Progress:
业务进展:
Twist Bioscience has strengthened its product offering, particularly in its Express portfolio, which includes clonal genes, gene fragments, DNA preps, and IgG proteins.
The company continues to expand its market share, particularly in the NGS tools portfolio which is seeing strong demand in rare disease and cancer diagnostics.
The Biopharma services segment marked a revenue pickup, attributed to an increased order volume which is expected to convert to revenue in three to nine months.
Strategic partnerships and collaborations with Illumina, Adicet Bio, and Element further bolster the company's industry position.
Twist Bioscience已经加强了其产品组合,尤其是在其Express系列中,包括克隆基因、基因片段、DNA制备和IgG蛋白。
该公司继续扩大其市场份额,尤其是在NGS工具组合方面,罕见疾病和癌症诊断需求旺盛。
生物制药服务部门的营收增长源于订单量增加,预计将在三至九个月内转化为营收。
与illumina、艾切托和Element的战略合作伙伴关系进一步巩固了公司在行业板块的地位。
Opportunities:
机会:
The ongoing expansion of the NGS and SynBio sectors coupled with increasing orders indicates a robust demand environment for Twist's innovative product lines.
The development and integration of proprietary enzymes presents a new market opportunity, enhancing product competitiveness and opening up new customer segments.
NGS和SynBio领域的持续扩张,以及订单增加,表明twist bioscience创新产品线存在强劲需求环境。
独家酶的开发和整合提供了新的市场机会,增强了产品竞争力,并开拓了新的客户群体。
Risks:
风险:
The gradual growth expected from new product segments, such as the DNA storage technology which is still under development, indicates a potential lag before these technologies significantly contribute to revenue.
预计新产品领域的逐步增长,例如仍在开发中的DNA存储技术,表明这些技术在显著贡献营收之前可能存在潜在的滞后。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由人工智能生成。内容准确性无法完全保证。如需更全面详情,请参阅IR网站。本文仅供投资者参考,不具有任何指导或推荐建议。